Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Deals

Migrasome Therapeutics Secures Over RMB100 Million in Angel+ Funding Round

Fineline Cube Aug 14, 2023

Beijing-based biotech startup Migrasome Therapeutics has reported raising upwards of RMB100 million in its angel...

Company Drug

CanSino BiologicsLaunches Phase III Trial for DTcP Vaccine in Infants and Young Children

Fineline Cube Aug 14, 2023

CanSino Biologics Inc. a leading China-based vaccines specialist (HKG: 6185), has announced the initiation of...

Policy / Regulatory

Hunan HSA Implements Direct BMI Fund Payments for VBP-Winning Drugs and Consumables

Fineline Cube Aug 11, 2023

The Hunan Healthcare Security Administration (HSA) bureau has released a notice stating that effective from...

Policy / Regulatory

SAMR and Nine Ministries Tighten Regulations on Forums and Conferences in China

Fineline Cube Aug 11, 2023

The State Administration for Market Regulation (SAMR) of China, in conjunction with nine other ministries,...

Company Drug

Cutia Therapeutics’ CU-10201 Enters Priority Review for Acne Treatment in China

Fineline Cube Aug 11, 2023

Dermatology therapy developer Cutia Therapeutics (HKG: 2487) has announced that its CU-10201, a 4% minocycline...

Company Deals

Huadong Medicine Secures Exclusive Rights to Arcutis’ Daxas in Greater China and South-East Asia

Fineline Cube Aug 11, 2023

Huadong Medicine Co., Ltd (SHE: 000963) has announced a significant licensing agreement with Arcutis (NASDAQ:...

Company Deals

Medtronic Partners with APMG to Advance Orthopedic Treatment Services in China

Fineline Cube Aug 11, 2023

US-based Medtronic Inc., (NYSE: MDT) has entered into a partnership with China’s private healthcare group...

Company Deals

Everest Medicines and Shanghai Pharmaceuticals Deepen Partnership for Drug Distribution in China

Fineline Cube Aug 11, 2023

China-based Everest Medicines (HKG: 1952) has announced a strategic partnership with Shanghai Pharmaceuticals marking a...

Company Drug

NMPA Greenlights Oricell Therapeutics’ OriCAR-017 for Clinical Trials in Multiple Myeloma

Fineline Cube Aug 11, 2023

The National Medical Products Administration (NMPA) has indicated on its website that Oricell Therapeutics Co.,...

Company Medical Device

Beijing Balance Medical Receives Approval for Innovative Expandable Artificial Heart Valve in China

Fineline Cube Aug 11, 2023

Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology company in China,...

Company Deals

WuXi Biologics and Boostimmune Forge Exclusive R&D Partnership

Fineline Cube Aug 11, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...

Company Deals

Antengene Corp. Secures Licensing Deal with Hansoh Pharmaceutical for Xpovio in China

Fineline Cube Aug 11, 2023

China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced a significant licensing agreement with...

Company

Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales

Fineline Cube Aug 11, 2023

Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the...

Company Legal / IP

Pfizer Faces Whistleblower Lawsuit Over Alleged FCPA Violations in China

Fineline Cube Aug 11, 2023

A former employee of Pfizer Inc., (NYSE: PFE), Frank Han, has filed a civil lawsuit...

Company

Organon Reports Q2 2023 Revenue Growth, Driven by Women’s Health and Biosimilars

Fineline Cube Aug 10, 2023

US-based Organon (NYSE: OGN) has reported its financial results for the second quarter of 2023,...

Company Deals

Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US...

Company

Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...

Company Deals

Poseida Therapeutics Secures $50 Million Investment from Astellas for Cell and Gene Therapy

Fineline Cube Aug 10, 2023

US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Completes Phase III Study for Myopia Treatment NVK002

Fineline Cube Aug 10, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Company Medical Device

Eyebright Medical Technology’s Intraocular Lenses Earn Fast-Track Status in China

Fineline Cube Aug 10, 2023

Beijing-based Eyebright Medical Technology Co., Ltd (SHE: 688050) has announced that its “intraocular lenses with...

Posts pagination

1 … 490 491 492 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.